Healthcare / Pharmaceutical RetailersTokyo
$5627.00
+175.00 (+3.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $10.5B · quality 74.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$197.6B
P/E
18.7x
↓EV/EBITDA
6.7x
↓ROE
6.5%
↑Gross Margin
16.3%
↓Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.0%
FCF CAGR
-14.8%
FCF margin
2.4%
FCF / Net income
1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $456.80B · net income $9.26B · FCF $10.96B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $456.80B | $456.80B | $399.82B | $358.74B | $316.25B |
| Net Income | $9.26B | $9.26B | $11.40B | $9.23B | $7.09B |
| EBITDA | $31.14B | $31.14B | $30.00B | $25.77B | $22.09B |
| EPS | 264.32 | 264.32 | 324.64 | 262.87 | 201.47 |
| Gross Margin | 16.3% | 16.3% | 14.9% | 15.0% | 15.8% |
| Operating Margin | 3.7% | 3.7% | 5.1% | 4.5% | 4.8% |
| Net Margin | 2.0% | 2.0% | 2.9% | 2.6% | 2.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.05 | 0.07 | 0.07 |
| Current Ratio | 0.92 | 0.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $10.96B | $10.96B | $10.50B | $8.11B | $17.74B |
| Returns | |||||
| ROE | 6.5% | 6.5% | 8.4% | 7.3% | 6.0% |
| Valuation | |||||
| P/E | 18.73 | 18.73 | 19.16 | 21.76 | 28.39 |
| EV/EBITDA | 6.71 | 6.71 | 5.89 | 6.32 | 6.80 |
| P/B | 1.38 | 1.38 | 1.61 | 1.59 | 1.69 |
| Growth & Yield | |||||
| Revenue Growth | 14.3% | 14.3% | 11.5% | 13.4% | — |
| EPS Growth | -18.6% | -18.6% | 23.5% | 30.5% | — |
| Dividend Yield | 3.7% | 3.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
23.6%
EPS terminal req.
$499.30
Spread vs growth
-42.2%
5Y implied EPS CAGR
18.0%
EPS terminal req.
$604.16
Spread vs growth
-36.6%
10Y implied EPS CAGR
13.9%
EPS terminal req.
$973.00
Spread vs growth
-32.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.6%
Start / end P/E
16.5x → 21.3x
EPS bridge
324.64 → 264.32
Residual
-5.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.